New Methods Of Treatment Of Ovarian Cancer.
Women with advanced ovarian cancer who hear eager chemotherapy directly into their stomach area may live at least one year longer than women who experience standard intravenous chemotherapy, a new study says. But this survival head start may come at the expense of more side effects. "The long-term benefits are quite significant," said study author Dr Devansu Tewari, director of gynecologic oncology at the Southern California Permanente Medical Group, in Orange County opinie. "There is no mug up of ovarian cancer treatments that has shown a greater survival advantage".
Intraperitoneal chemotherapy involves bathing the abdominal close with chemotherapy agents. By contrast, intravenous (IV) chemotherapy is delivered throughout the body via the bloodstream prices. The US National Cancer Institute currently recommends intraperitoneal analysis for women with ovarian cancer who have had prominent surgery to obliterate the tumor.
The 10-year follow-up data from two studies of nearly 900 women with advanced ovarian cancer will be presented Saturday at the annual assembly of the Society of Gynecologic Oncology, in Los Angeles. In 2013, more than 22000 American women will be diagnosed with ovarian cancer, and more than 14000 will cash in one's chips from the disease, according to the US National Cancer Institute. There are no prehistoric screening tests for ovarian cancer, which is why it is often diagnosed when the cancer has already extent farthest of the ovaries.
For this reason, survival rates tend to be very low. In the new study, women who received the intraperitoneal curing were 17 percent more likely to survive longer than those who got IV chemotherapy. On average, women in the intraperitoneal place survived for more than five years, while those who received IV chemotherapy survived for about four years, the workroom found. But survival benefits aside, intraperitoneal chemotherapy does talk a greater risk of side effects - such as abdominal agony and numbness in the hands and feet - and not all women can tolerate this high concentration of cancer-killing drugs.
The drugs are also wrapped up more slowly, providing more exposure to the medicine. The same properties that make the intraperitoneal cure more effective likely play a role in causing more side effects, the researchers said. In general, six cycles of intraperitoneal chemotherapy are recommended, and can be given in inpatient or outpatient settings. The more cycles the women completed, the greater their survival advantage, the look showed.
